Nyxoah reported strong Q1 2026 results, driven by the successful U.S. launch of Genio, which achieved a 25% sequential U.S. revenue growth. Gross revenue reached €6.7 million, with net revenue at €6.4 million, a significant increase from Q1 2025. The company also highlighted continued clarity and 100% approval rates for reimbursement in the U.S. market, with Medicare issuing new C-Codes for Genio. Nyxoah trained 62 new surgeons and activated 34 new accounts, demonstrating strong operational expansion. The company maintains a positive outlook for full-year 2026 worldwide net revenue and gross margin, expecting continued strong sequential growth in U.S. net revenue.
Nyxoah SA key market context on AlphaOS includes Sector: Healthcare; Industry: Medical Instruments & Supplies; Market capitalization: $68.41M; Recent price: $1.59. Figures update as market data and SEC filings are ingested.
Use this NYXH research hub for earnings transcripts, SEC filings, opportunity scoring, news, and knowledge-graph relationships. Content is for research and education only — not investment advice.